↓ Skip to main content

The Hydrogen Sulfide Releasing Molecule Acetyl Deacylasadisulfide Inhibits Metastatic Melanoma

Overview of attention for article published in Frontiers in Pharmacology, February 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
14 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The Hydrogen Sulfide Releasing Molecule Acetyl Deacylasadisulfide Inhibits Metastatic Melanoma
Published in
Frontiers in Pharmacology, February 2017
DOI 10.3389/fphar.2017.00065
Pubmed ID
Authors

Paola De Cicco, Elisabetta Panza, Chiara Armogida, Giuseppe Ercolano, Orazio Taglialatela-Scafati, Yalda Shokoohinia, Rosa Camerlingo, Giuseppe Pirozzi, Vincenzo Calderone, Giuseppe Cirino, Angela Ianaro

Abstract

Melanoma is the most common form of skin cancer. Given its high mortality, the interest in the search of preventive measures, such as dietary factors, is growing significantly. In this study we tested, in vitro and in vivo, the potential anti-cancer effect of the acetyl deacylasadisulfide (ADA), a vinyl disulfide compound, isolated and purified from asafoetida a foul-smelling oleo gum-resin of dietary and medicinal relevance. ADA markedly suppressed proliferation of human melanoma cell lines by inducing apoptosis. Moreover, treatment of melanoma cells with ADA reduced nuclear translocation and activation of NF-κB, decreased the expression of the anti-apoptotic proteins c-FLIP, XIAP, and Bcl-2 and inhibited the phosphorylation and activation of both AKT and ERK proteins, two of the most frequently deregulated pathways in melanoma. Finally, the results obtained in vitro were substantiated by the findings that ADA significantly and dose-dependently reduced lung metastatic foci formation in C57BL/6 mice. In conclusion, our findings suggest that ADA significantly inhibits melanoma progression in vivo and could represent an important lead compound for the development of new anti-metastatic agents.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 14%
Student > Master 2 14%
Lecturer 1 7%
Professor 1 7%
Student > Doctoral Student 1 7%
Other 2 14%
Unknown 5 36%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 3 21%
Biochemistry, Genetics and Molecular Biology 2 14%
Nursing and Health Professions 1 7%
Agricultural and Biological Sciences 1 7%
Medicine and Dentistry 1 7%
Other 1 7%
Unknown 5 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2017.
All research outputs
#20,407,586
of 22,957,478 outputs
Outputs from Frontiers in Pharmacology
#10,137
of 16,230 outputs
Outputs of similar age
#271,844
of 312,054 outputs
Outputs of similar age from Frontiers in Pharmacology
#127
of 196 outputs
Altmetric has tracked 22,957,478 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,230 research outputs from this source. They receive a mean Attention Score of 5.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,054 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 196 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.